Publicaciones científicas
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Yi Lin 1 , Lugui Qiu 2 , Saad Usmani 3 , Chng Wee Joo 4 , Luciano Costa 5 , Benjamin Derman 6 , Juan Du 7 , Hermann Einsele 8 , Carlos Fernandez de Larrea 9 , Roman Hajek 10 , P Joy Ho 11 , Efstathios Kastritis 12 , Joaquin Martinez-Lopez 13 , Maria-Victoria Mateos 14 , Joseph Mikhael 15 , Philippe Moreau 16 , Chandramouli Nagarajan 17 , Ajay Nooka 18 , Michael O'Dwyer 19 , Fredrik Schjesvold 20 , Surbhi Sidana 21 , Niels Wcj van de Donk 22 , Katja Weisel 23 , Sonja Zweegman 22 , Noopur Raje 24 , Paula Rodriguez Otero 25 , Larry D Anderson Jr 26 , Shaji Kumar 27 , Tom Martin 28 ; International Myeloma Working Group
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.
CITA DEL ARTÍCULO Lancet Oncol. 2024 May 28:S1470-2045(24)00094-9
Nuestros autores
